QDVG:F:F-iShares S&P 500 Health Care Sector UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 11.026

Change

+0.03 (+0.25)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-12 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.28 (-1.06%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.35 (-0.70%)

USD 108.20B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 93.32B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.28 (-0.51%)

USD 86.92B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 53.24B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.23 (+0.24%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 51.19B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 41.09B
0ZC:F Zscaler Inc

+0.42 (+0.28%)

USD 37.92B

ETFs Containing QDVG:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.01% 83% B 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.01% 80% B- 66% D+
Trailing 12 Months  
Capital Gain 17.86% 72% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.86% 69% C- 62% D
Trailing 5 Years  
Capital Gain 83.16% 93% A 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.16% 93% A 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 12.10% 82% B 74% C
Dividend Return 12.10% 80% B- 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.05% 61% D- 85% B
Risk Adjusted Return 109.51% 99% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike